269 related articles for article (PubMed ID: 10025933)
1. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity.
Tselepis AD; Elisaf M; Besis S; Karabina SA; Chapman MJ; Siamopoulou A
Arthritis Rheum; 1999 Feb; 42(2):373-83. PubMed ID: 10025933
[TBL] [Abstract][Full Text] [Related]
2. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
[TBL] [Abstract][Full Text] [Related]
3. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.
McCall MR; La Belle M; Forte TM; Krauss RM; Takanami Y; Tribble DL
Biochim Biophys Acta; 1999 Jan; 1437(1):23-36. PubMed ID: 9931415
[TBL] [Abstract][Full Text] [Related]
4. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
Karabina SA; Elisaf M; Bairaktari E; Tzallas C; Siamopoulos KC; Tselepis AD
Eur J Clin Invest; 1997 Jul; 27(7):595-602. PubMed ID: 9263748
[TBL] [Abstract][Full Text] [Related]
5. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis.
De Geest B; Stengel D; Landeloos M; Lox M; Le Gat L; Collen D; Holvoet P; Ninio E
Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):E68-75. PubMed ID: 11031226
[TBL] [Abstract][Full Text] [Related]
6. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
Brites FD; Verona J; Schreier LE; Fruchart JC; Castro GR; Wikinski RL
Arch Med Res; 2004; 35(3):235-40. PubMed ID: 15163466
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid.
Kujiraoka T; Hattori H; Ito M; Nanjee MN; Ishihara M; Nagano M; Iwasaki T; Cooke CJ; Olszewski WL; Stepanova IP; Egashira T; Miller NE
Atherosclerosis; 2004 Sep; 176(1):57-62. PubMed ID: 15306175
[TBL] [Abstract][Full Text] [Related]
8. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.
Milionis HJ; Tambaki AP; Kanioglou CN; Elisaf MS; Tselepis AD; Tsatsoulis A
Thyroid; 2005 May; 15(5):455-60. PubMed ID: 15929667
[TBL] [Abstract][Full Text] [Related]
9. Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.
Tsimihodimos V; Karabina SA; Tambaki AP; Bairaktari E; Miltiadous G; Goudevenos JA; Cariolou MA; Chapman MJ; Tselepis AD; Elisaf M
J Lipid Res; 2002 Feb; 43(2):256-63. PubMed ID: 11861667
[TBL] [Abstract][Full Text] [Related]
10. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.
Karabina SA; Elisaf MC; Goudevenos J; Siamopoulos KC; Sideris D; Tselepis AD
Atherosclerosis; 1996 Aug; 125(1):121-34. PubMed ID: 8831934
[TBL] [Abstract][Full Text] [Related]
11. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.
Kujiraoka T; Iwasaki T; Ishihara M; Ito M; Nagano M; Kawaguchi A; Takahashi S; Ishi J; Tsuji M; Egashira T; Stepanova IP; Miller NE; Hattori H
J Lipid Res; 2003 Oct; 44(10):2006-14. PubMed ID: 12867534
[TBL] [Abstract][Full Text] [Related]
12. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
Tselepis AD; Goudevenos JA; Tambaki AP; Michalis L; Stroumbis CS; Tsoukatos DC; Elisaf M; Sideris DA
Cardiovasc Res; 1999 Jul; 43(1):183-91. PubMed ID: 10536703
[TBL] [Abstract][Full Text] [Related]
13. Urine of patients with nephrotic syndrome contains the plasma type of PAF-acetylhydrolase associated with lipoproteins.
Balafa OC; Karabina SA; Pappas CA; Elisaf M; Tselepis AD; Siamopoulos KC
Nephron Physiol; 2004; 97(3):p45-52. PubMed ID: 15292677
[TBL] [Abstract][Full Text] [Related]
14. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
Noto H; Hara M; Karasawa K; Iso-O N; Satoh H; Togo M; Hashimoto Y; Yamada Y; Kosaka T; Kawamura M; Kimura S; Tsukamoto K
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):829-35. PubMed ID: 12649088
[TBL] [Abstract][Full Text] [Related]
15. Activity and distribution of plasma platelet-activating factor acetylhydrolase in women with gestational diabetes mellitus and their neonates.
Gao Q; He GL; Zhang L; Bai H; Liu XH; Fan P
Diabetes Metab Res Rev; 2016 Sep; 32(6):634-42. PubMed ID: 26789131
[TBL] [Abstract][Full Text] [Related]
16. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
Wan DH; Fan P; Bai H; Song Q; Liu HW
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
Tsimihodimos V; Karabina SA; Tambaki AP; Bairaktari E; Goudevenos JA; Chapman MJ; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):306-11. PubMed ID: 11834533
[TBL] [Abstract][Full Text] [Related]
18. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
Papavasiliou EC; Gouva C; Siamopoulos KC; Tselepis AD
Nephrol Dial Transplant; 2006 May; 21(5):1270-7. PubMed ID: 16421163
[TBL] [Abstract][Full Text] [Related]
19. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase.
Tsironis LD; Mitsios JV; Milionis HJ; Elisaf M; Tselepis AD
Cardiovasc Res; 2004 Jul; 63(1):130-8. PubMed ID: 15194469
[TBL] [Abstract][Full Text] [Related]
20. [Positive and negative effects of progestins on platelet-activating factor acetylhydrolase activity in rat plasma].
Fujikami F; Yasuda K; Sawaragi I
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Jun; 47(6):539-46. PubMed ID: 7608617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
